Veterinary Oncology Market Accelerates Amid Rising Pet Cancer Incidence

• Rising pet cancer incidence driving expansion of specialized treatment pipelines worldwide, illustrating evolving market dynamics.
  
  • Adoption of immunotherapies and targeted drugs shaping Veterinary Oncology Market trends in 2024.
  
  • Accelerated approvals boostingVeterinary Oncology Market Trendrevenue for novel oncology therapeutics.
  
  • Zoetis and Elanco captured significant Veterinary Oncology Market share in North America, per report.

Global veterinary oncology market is estimated to be valued at USD 810.5 Mn in 2025 and is expected to reach USD 1,770.6 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 11.8% from 2025 to 2032.

• Market report details growth strategies in diagnostics and therapies.
  
  • Detailed market analysis shows immunotherapy segment leading industry share and business growth.
  
  • OurVeterinary Oncology Marketresearch emphasizes expanding market scope across pet oncology segments.
  
  • Market forecast indicates sustained market growth through 2032 fueled by emerging segments.
  
  
  
  Market Drivers
  
  • Technological Advancements: Rapid proliferation of immunotherapies and targeted oncology drugs for companion animals boosting therapeutic options and reflecting pivotal industry trends.
  
  • Industry Example: AB Science's masitinib prescriptions surged 25% in 2024, validating growing clinician confidence in molecular-targeted treatments.
  
  • Market Impact: Enhanced treatment success rates have elevated market revenue projections by over 12% in 2025 and rebalanced Veterinary Oncology Market share toward specialized therapy providers.
  
  • Forward Outlook: Continued R&D investments expected to drive a 15% increase in industry size by 2026, unlocking new market opportunities and sustaining long-term market growth.
  
  
  
  PEST Analysis
  
  • Political: Government grants increased by 18% in 2025 for veterinary cancer research across the EU, driving policy support and shaping market opportunities.
  
  • Economic: Rising pet care expenditure, projected to exceed USD 300 Bn globally in 2024, has elevated veterinary oncology budgets, creating market opportunities and highlighting cost-related market restraints.
  
  • Social: Pet owners in North America now spend 32% more on advanced cancer treatments compared to 2023, reflecting changing attitudes toward animal health, offering critical market insights for segment expansion.
  
  • Technological: Integration of AI-driven diagnostics by companies like Merck Animal Health in 2024 has enhanced early tumor detection, fueling market growth, innovation pipelines, and expanding market segments.
  
  
  
  Promotion and Marketing Initiative
  
  • Virtual Education Campaigns: In 2025, Zoetis launched an online symposium series on canine oncology, garnering over 5,000 veterinarian registrations and boosting program adoption by 18%.
  
  • Digital Awareness Drives: Elanco's 2024 social media initiative under #PetCancerCare reached 2 million impressions, enhancing veterinary oncology service inquiries by 22% and supporting market growth.
  
  
  
  Key Players
  
  • Leading market players and companies are investing heavily in R&D to expand veterinary oncology portfolios.
  
  • Zoetis Inc.
  
  • Elanco
  
  • AB Science
  
  • Boehringer Ingelheim International GmbH
  
  • Zenoaq
  
  • VetD
  
  • Merck Animal Health
  
  • Ceva Santé Animale
  
  • Vetoquinol
  
  • Genoscience Pharma
  
  • Aratana Therapeutics
  
  • Karyopharm Therapeutics
  
  • Zoetis expanded oncology diagnostics labs in Europe in 2025, increasing market coverage by 15%.
  
  • Elanco introduced a novel canine cancer vaccine in 2024, driving a 20% uplift in product uptake.
  
  • AB Science partnered with veterinary hospitals in 2025, enhancing clinical trial enrollment and improving research outcomes.
  
  
  
  FAQs
  
  Q1: Who are the dominant players in the Veterinary Oncology market?
  
  A1: Zoetis, Elanco, AB Science, and Boehringer Ingelheim dominate product offerings and geographic reach.
  
  
  
  Q2: What will be the size of the Veterinary Oncology market in the coming years?
  
  A2: Expected to grow from USD 810.5 Mn in 2025 to USD 1,682.8 Mn by 2032 at 11% CAGR.
  
  
  
  Q3: Which animal segment offers the largest growth opportunity?
  
  A3: The canine segment leads due to high pet ownership and rapid adoption of advanced therapies.
  
  
  
  Q4: How will market development trends evolve over the next five years?
  
  A4: Markets will shift toward immunotherapies, AI diagnostics, and personalized cancer vaccines.
  
  
  
  Q5: What is the nature of the competitive landscape and challenges in the Veterinary Oncology market?
  
  A5: The field is fragmented; primary restraints include regulatory complexity and high treatment costs.
  
  
  
  Q6: What go-to-market strategies are commonly adopted in the Veterinary Oncology market?
  
  A6: Firms use digital education, clinician partnerships, and targeted outreach to boost therapy uptake.

Get this report in Japanese language- 獣医腫瘍学市場

Get this report in Korean language- 수의 종양학 시장

Read more articles related to this industry-

Recent Developments in Active Pharmaceutical Ingredients Industry

Regulatory Standards for Active Pharmaceutical Ingredients: Ensuring Safety and Compliance

How Active Pharmaceutical Ingredients Are Manufactured: Key Processes and Techniques

About Author:                    

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)